Insider buying
~$14K30K sh @ $0.46
Traded Dec 18, 2024 · filed 1 day later
Since the trade −96.5% · S&P 500 +17.7% · to Nov 20
A Scilex director paid $14K out of pocket for Scilex shares. Shares held went up 27% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SCLX · NASDAQ · Biological Products, (No Diagnostic Substances)
Scilex Holding (SCLX) · oqro.io/stocks/SCLX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Scilex Holding was filed in the last 90 days. The latest on record was on Dec 19, 2024.
Since 2023, Scilex Holding insiders reported 15 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
No open-market sale by an insider of Scilex Holding (SCLX) was filed with the SEC in the last 90 days.
No trade in Scilex Holding (SCLX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.5658−0.0842 (−12.95%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−97.0% (−$18.38) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $18.95 on Nov 20, 2025 to $0.5658 on Nov 20, 2026 (−97.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Palo Alto, Ca.
Last 12 months
−97.0%
Market value
$5.45M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 132K shares sold short (1.4% of shares outstanding), −10.9% vs the previous count, 3.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$7.64M
−22.8% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $566K, at Jun 30, 2026
Net income, last 12 months
−$465M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 8, 2024.
Revenue, fiscal 2025
$30.3M
−46.5% vs the year before
Net income, fiscal 2025
−$374M
A loss for the year
Shares outstanding
8.49M
As of Aug 10, 2026
In fiscal 2024 the company spent $8.65M on dividends. Cash actually paid, from its cash-flow statement.
Insider buying
Traded Dec 18, 2024 · filed 1 day later
Since the trade −96.5% · S&P 500 +17.7% · to Nov 20
A Scilex director paid $14K out of pocket for Scilex shares. Shares held went up 27% with this purchase.
Insider buying
Traded Oct 31, 2024 · filed the same day
Since the trade −98.3% · S&P 500 +21.3% · to Nov 20
Scilex's Executive Chairperson paid $8.4K out of pocket for Scilex shares. 6 other people at Scilex bought some too, in the same month.
Insider buying
Traded Oct 29, 2024 · filed the same day
Since the trade −98.4% · S&P 500 +18.6% · to Nov 20
A Scilex director paid $32K out of pocket for Scilex shares. 6 other people at Scilex bought some too, in the same month. Shares held went up 41% with this purchase.
Insider buying
Traded Oct 17, 2024 · filed 1 day later
Since the trade −98.3% · S&P 500 +18.4% · to Nov 20
A Scilex director paid $19K out of pocket for Scilex shares. 6 other people at Scilex bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Oct 17, 2024 · filed 1 day later
Since the trade −98.3% · S&P 500 +18.4% · to Nov 20
Scilex's Executive Chairperson paid $9.7K out of pocket for Scilex shares. 6 other people at Scilex bought some too, in the same month. It was the first purchase in over a year.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Said its annual or quarterly report would be late
“Scilex Holding Company (the “Company”) is unable to file its Quarterly Report on Form 10-Q for its fiscal quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense for the reason described below. As disclosed in the Company’s Current Report on Form 8-K filed on November 17, 2026 (the “Form 8-K”), on November 11, 2026, the audit committee (the “Committe”
NT 10-Q on sec.govChanged auditor
8-K on sec.govSaid its annual or quarterly report would be late
“Scilex Holding Company (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by May 15, 2026, the prescribed due date, because it requires more time to finalize its financial statements to be included in such Form 10-Q, including the consolidation of Vivasor Holding Company. The”
NT 10-Q on sec.govSaid its annual or quarterly report would be late
“Scilex Holding Company (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) by March 31, 2026, the prescribed due date, because it requires more time to finalize its financial statements to be included in such Form 10-K, including the consolidation of Vivasor Holding Company. The C”
NT 10-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Scilex Holding reported 15 open-market purchases and 1 sale since 2023; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $357K15×15 trades | — |
| 2023 | — | —1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
No Schedule 13D or 13G filing on SCLX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: 49.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (9.3% on ATS, 40.4% with other brokers), above its 26-week average of 43.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (16.0%), POSIT (11.6%), INSTINCT X (11.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 17,000 words.
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018, in-licensed two commercial products in 2022 and 2023, and are developing our late-stage pipeline.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Apr 10, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
Oct 8, 2024
More than 30 days ago
Next results, expected
Not announced
Purchases after results
67%
10 of 15 insider purchases since 2023 came within 30 days after a results announcement
From Scilex Holding's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Scilex Holding's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Apr 10, 2026, compared with the one filed Mar 31, 2025. Read the filing
And 11 more headings in the filing.
The information required by this Item is incorporated by reference to Note 13 titled “Commitments and Contingencies” and Note 16 titled “Subsequent Events” of the Notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Apr 10, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.